Oral N-Acetylcysteine on Diabetic Macular Edema
Effect of Oral N-Acetylcysteine on Diabetic Macular Edema in Type 2 Diabetic Patients With Diabetic Retinopathy
Diabetic retinopathy (DR) is one of the leading causes of preventable visual impairment among working-age adults, with diabetic macular edema (DME) representing one of its most important vision-threatening complications. Diabetic macular edema develops when diabetes-associated retinal vascular dysfunction leads to disruption of the blood-retinal barrier (BRB), allowing fluid and plasma components to accumulate within the retinal tissue and impair macular function. The development and persistence of DME involve a complex interplay between vascular, inflammatory, metabolic, and oxidative mechanisms.
Hyperglycemia is a central driver of the molecular abnormalities underlying diabetic retinal injury. Chronic exposure to elevated glucose activates several interrelated pathways, including the polyol, advanced glycation end-products (AGEs), protein kinase C (PKC), and hexosamine pathways. These metabolic disturbances promote the generation of reactive oxygen species (ROS), inflammatory signaling, endothelial dysfunction, and progressive impairment of the retinal neurovascular unit. Together, these processes contribute to damage to endothelial cells, pericytes, Müller cells, and other retinal components, ultimately compromising the integrity of the BRB.
Oxidative stress is therefore considered an important component of the pathophysiology of DR and DME. Excessive ROS production can directly damage cellular structures and can also amplify inflammatory and angiogenic signaling. This may increase the expression of several mediators implicated in retinal vascular dysfunction. The resulting vascular instability and increased permeability facilitate fluid extravasation into the retinal layers and contribute to the development and progression of DME.
Malondialdehyde (MDA), a product of lipid peroxidation, is widely used as a marker of oxidative damage. Increased MDA concentrations have been reported in patients with diabetic retinopathy and have been associated with the presence or severity of retinal disease, supporting the involvement of oxidative stress in diabetic retinal injury. Assessment of MDA may therefore provide a useful systemic indicator of the oxidative component of the disease process.
Angiopoietin-2 (Ang-2), an important regulator of vascular stability, has also been implicated in diabetic retinal vascular dysfunction. Increased Ang-2 can promote endothelial destabilization and enhance vascular permeability, particularly in the presence of inflammatory and VEGF-related signaling. Thus, oxidative stress and angiogenic dysregulation may represent interconnected components of the vascular injury that ultimately leads to BRB disruption and retinal fluid accumulation.
Current management of DME relies predominantly on ophthalmic interventions, with corticosteroids and laser photocoagulation having roles in selected clinical settings. Although these approaches have substantially improved visual and anatomical outcomes, persistent or recurrent edema occurs in a proportion of patients, reflecting the multifactorial nature of DME and the involvement of various pathways.
N-acetylcysteine (NAC) is a thiol-containing compound and a precursor of L-cysteine and reduced glutathione. In addition to its established mucolytic properties, NAC has antioxidant activity through direct scavenging of reactive oxygen species and, importantly, through restoration of intracellular glutathione availability. Its ability to modulate oxidative stress has led to extensive investigation of NAC in a variety of clinical conditions characterized by oxidative and inflammatory injury.
Experimental evidence suggests that attenuation of oxidative stress with NAC may reduce diabetes-related retinal injury and suppress the expression of vascular and inflammatory mediators, including VEGF and intercellular adhesion molecule-1 (ICAM-1). However, the potential clinical relevance of oral NAC in patients with diabetic retinal disease remains insufficiently characterized.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Esraa Farag
- 電話番号:+201026156317
- メール:Esraa.AhmedF@pharm.psu.edu.eg
研究場所
-
-
-
Damietta、エジプト
- 募集
- Al-Azhar Hospital, Damietta
-
コンタクト:
- Esraa Farag
- 電話番号:+201026156317
- メール:Esraa.AhmedF@pharm.psu.edu.eg
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with type 2 diabetes mellitus
- Adults aged >18 and <70 years.
- Patients of either sex.
- Patients with center-involving diabetic macular edema (CI-DME) with best-corrected visual acuity of 20/25 or better in the study eye and who are considered eligible for observation without immediate anti-VEGF treatment according to predefined ophthalmological criteria.
- Clear ocular media allowing good quality OCT macula imaging.
Exclusion Criteria:
- Presence of ophthalmic diseases other than diabetic retinopathy that may affect macular thickness or visual function (Age-related macular degeneration, epiretinal membrane, vitreomacular traction, significant cataract affecting visual assessment, retinal vein occlusion, uveitis, glaucoma, etc.)
- Pregnancy or breastfeeding.
- Current use of systemic antioxidant supplements or antioxidant therapy that could interfere with the study outcomes.
- History of ocular surgery or laser.
- Systemic diseases affecting retinal microvasculature other than diabetes (e.g., uncontrolled hypertension, vasculitis).
- Poor image quality (media opacity, interferes with OCT imaging).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:コントロール
|
|
|
アクティブコンパレータ:NAC group
|
N-acetylcysteine (NAC) at a total daily dose of 1200 mg, administered as 600 mg twice daily |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Central Subfield Thickness (CST) Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)
時間枠:3 months
|
Central subfield thickness (CST), defined as the retinal thickness within the central 1-mm subfield centered on the fovea, will be measured using spectral-domain optical coherence tomography (SD-OCT; DRI OCT Triton, Topcon, Japan). The change in CST from baseline to the end of the 3-month intervention period will be evaluated. |
3 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Serum Malondialdehyde (MDA) Concentration
時間枠:3 months
|
Serum malondialdehyde (MDA), a biomarker of oxidative stress, will be measured at baseline and at the end of the 3-month intervention period. The change in serum MDA concentration from baseline to 3 months will be assessed. |
3 months
|
|
Change from Baseline in Serum Angiopoietin-2 (Ang-2) Concentration
時間枠:3 months
|
Serum angiopoietin-2 (Ang-2), a biomarker of vascular destabilization and angiogenic signaling, will be measured at baseline and at the end of the 3-month intervention period. The change in serum Ang-2 concentration from baseline to 3 months will be assessed. |
3 months
|
|
Change from Baseline in Best-Corrected Visual Acuity (BCVA) Measured Using a Standardized Tumbling E Chart
時間枠:3 months
|
Best-corrected visual acuity (BCVA) will be assessed using a standardized Tumbling E chart at a distance of 6 meters with appropriate refractive correction. Visual acuity will be recorded according to the predefined chart scoring system and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. The change in BCVA from baseline to 3 months will be evaluated. |
3 months
|
|
Number of Participants Requiring Rescue Therapy for Diabetic Macular Edema During the Study Period
時間枠:3 months
|
The number of participants requiring rescue ophthalmological treatment due to clinically significant visual deterioration or worsening of diabetic macular edema during the 3-month follow-up period will be recorded. Rescue treatments may include anti-VEGF therapy, intravitreal corticosteroids, or laser treatment, according to the treating ophthalmologist's clinical judgment and predefined study criteria. |
3 months
|
|
Number of Participants Experiencing at Least One Adverse Event
時間枠:3 months
|
The number of participants experiencing at least one adverse event during the intervention period will be recorded. Adverse events will be monitored through weekly telephone follow-up and mont |
3 months
|
|
Number of Participants Experiencing at Least One Serious Adverse Event
時間枠:3 months
|
The number of participants experiencing at least one serious adverse event during the intervention period will be recorded and documented, with appropriate clinical management and assessment of the possible relationship to the study medication. |
3 months
|
|
Number of Participants Discontinuing Study Medication Due to Adverse Events or Intolerance
時間枠:3 months
|
The number of participants who discontinue the study medication because of adverse events, intolerance, or safety concerns during the intervention period will be recorded. |
3 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- NAC&DME
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。